Skip to main content
. 2018 Aug 31;33(1):1209–1225. doi: 10.1096/fj.201800876R

Figure 5.

Figure 5

Atorvastatin (Ator) and pravastatin (Prava) treatment reduced LDL-C, but only Ator increased CK serum levels. Five weeks after statin treatment (5 mg/kg/d orally), peripheral blood was collected for serological analysis. A) Direct LDL-C (in mg/dl, Veh 14.38 ± 0.92, Ator 9.25 ± 0.77, and Prava 11.78 ± 0.64; n = 8–9 each). Means ± sem. ***P < 0.0004, Veh vs. Ator (1-way ANOVA with Tukey post hoc comparison). B) HDL-C (mg/dl: Veh 82.63 ± 2.44, Ator 81.50 ± 6.27, and Prava 95.33 ± 3.3, n = 8–9 each). Means ± sem. *P < 0.025, Veh vs. Prava; *P < 0.016 Ator vs. Prava. C) Total-cholesterol (mg/dl: Veh 125.8 ± 2.9, Ator 112.9 ± 10.06, and Prava 153.8 ± 5.77; n = 8–9 each). Means ± sem. *P < 0.02, Veh vs. Prava; ***P < 0.001, Ator vs. Prava. D) Triglycerides (mg/dl: Veh 79.88 ± 16.5, Ator 60.13 ± 9.29, and Prava 79.89 ± 5.23; n = 8–9 each). Means ± sem. E) Albumin (g/dl: Veh 2.8 ± 0.1, Ator 2.7 ± 0.07, and Prava 2.77 ± 0.07. Means ± sem. F) CK (IU/L: Veh 132.3 ± 14.8, Ator 388.0 ± 69.43, and Prava 182.7 ± 28.45). Means ± sem, Veh vs. Ator, P < 0.01). Veh, vehicle. Data (n = 8–9/group) were analyzed with 1-way ANOVA followed by Tukey’s post hoc multiple comparison, and values of P < 0.05 were considered significant.